Form 4 Filing for CRISPR Therapeutics AG

This filing details a Form 4 submission for CRISPR Therapeutics AG (CRSP) concerning stock options granted to John Greene, who is a director. On June 5, 2026, 13,000 stock options were granted with a purchase price of $0.0 per share, exercisable for Common Shares. These options are set to vest in 12 equal monthly installments starting June 30, 2026, with the final vesting on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting. The options expire on June 5, 2036. Mr. Greene acquired these options directly, and following this transaction, he holds 13,000 shares underlying these options.